Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis
Overview
Authors
Affiliations
Epigenetic regulators, when genomically altered, may become driver oncogenes that mediate otherwise unexplained pro-oncogenic changes lacking a clear genetic stimulus, such as activation of the WNT/β-catenin pathway in melanoma. This study identifies previously unrecognized recurrent activating mutations in the G9a histone methyltransferase gene, as well as G9a genomic copy gains in approximately 26% of human melanomas, which collectively drive tumor growth and an immunologically sterile microenvironment beyond melanoma. Furthermore, the WNT pathway is identified as a key tumorigenic target of G9a gain-of-function, via suppression of the WNT antagonist DKK1. Importantly, genetic or pharmacologic suppression of mutated or amplified G9a using multiple and models demonstrates that G9a is a druggable target for therapeutic intervention in melanoma and other cancers harboring G9a genomic aberrations. SIGNIFICANCE: Oncogenic G9a abnormalities drive tumorigenesis and the "cold" immune microenvironment by activating WNT signaling through DKK1 repression. These results reveal a key druggable mechanism for tumor development and identify strategies to restore "hot" tumor immune microenvironments..
Ghosh K, Huang Y, Jin D, Chen S, Pan H J Neurosci. 2025; 45(6).
PMID: 39824634 PMC: 11800753. DOI: 10.1523/JNEUROSCI.1790-24.2024.
G9a in Cancer: Mechanisms, Therapeutic Advancements, and Clinical Implications.
Ni Y, Shi M, Liu L, Lin D, Zeng H, Ong C Cancers (Basel). 2024; 16(12).
PMID: 38927881 PMC: 11201431. DOI: 10.3390/cancers16122175.
The Role and Mechanism of the Histone Methyltransferase G9a in Tumors: Update.
Zhou H, Gui J, Zhu L, Mi Y Onco Targets Ther. 2024; 17:449-462.
PMID: 38832355 PMC: 11146345. DOI: 10.2147/OTT.S451108.
Yang C, Ma S, Zhang J, Han Y, Wan L, Zhou W Proc Natl Acad Sci U S A. 2024; 121(23):e2317790121.
PMID: 38814866 PMC: 11161775. DOI: 10.1073/pnas.2317790121.
Wang S, Xiong Y, Jang M, Park K, Donahue M, Velez J Mol Ther. 2024; 32(8):2662-2675.
PMID: 38796700 PMC: 11405540. DOI: 10.1016/j.ymthe.2024.05.034.